Rock Springs Capital Management’s Xilio Therapeutics XLO Stock Holding History

Rock Springs Capital Management’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-214,519	Closed	-$2.87M	–	109
2024 Q4	$2.87M	Hold	214,519	–	–	0.11%	88
2024 Q3	$2.37M	Hold	214,519	–	–	0.08%	94
2024 Q2	$2.85M	Buy	214,519 +111,608	+108%	+$1.75M	0.09%	97
2024 Q1	$1.56M	Hold	102,911	–	–	0.04%	110
2023 Q4	$792K	Hold	102,911	–	–	0.02%	101
2023 Q3	$3.04M	Hold	102,911	–	–	0.08%	92
2023 Q2	$3.77M	Hold	102,911	–	–	0.09%	94
2023 Q1	$4.57M	Buy	102,911 +5,563	+6%	+$244K	0.11%	91
2022 Q4	$3.67M	Hold	97,348	–	–	0.09%	95
2022 Q3	$3.97M	Hold	97,348	–	–	0.1%	99
2022 Q2	$3.98M	Buy	97,348 +12,270	+14%	+$649K	0.12%	101
2022 Q1	$8.42M	Hold	85,078	–	–	0.21%	88
2021 Q4	$19.1M	Buy	+85,078	New	+$20.3M	0.44%	66

Other funds holding XLO

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Rock Springs Capital Management's XLO Position: Q1 2025 in Review

Rock Springs Capital Management sold out of Xilio Therapeutics (XLO) in Q1 2025, closing a stake of 214,519 shares — an estimated $2.87M sold.

Rock Springs Capital Management first reported a position in XLO in Q4 2021 and held it in 13 quarters. The position peaked at $19.1M in Q4 2021. 35 funds tracked by Wall St. Rank hold XLO as of Q1 2025.

Rock Springs Capital Management reported no remaining Xilio Therapeutics position as of Q1 2025 after selling out during the quarter.
Rock Springs Capital Management sold 214,519 Xilio Therapeutics shares in Q1 2025, an estimated $2.87M.
Rock Springs Capital Management first reported a position in Xilio Therapeutics in Q4 2021 and held it in 13 quarters.
Rock Springs Capital Management's Xilio Therapeutics position peaked at $19.1M in Q4 2021.
35 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2025.

Based on Rock Springs Capital Management's 13F filing for Q1 2025, filed 15 May 2025.